Company intelligence / Profile preview

Corstasis Pharmaceuticals

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Corstasis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with heart failure. Founded by a team of experts in cardiovascular drug discovery, the company focuses on modulating the cardiac sarcomere to improve heart function. Its lead program, CSP-001, is a small molecule designed to treat heart failure with preserved ejection fraction (HFpEF) by targeting specific mechanisms of cardiac contraction and relaxation. Corstasis aims to address the significant unmet need in cardiovascular medicine through precision-engineered therapeutics.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Corstasis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corstasis Pharmaceuticals.

Explore the full profile